Concord Biotech Limited (NSE:CONCORDBIO)
India · Delayed Price · Currency is INR 1,399.00
+25.40 (1.85%)
Oct 1, 2026, 3:30 PM IST
Concord Biotech Ratios and Metrics
Market cap in millions INR. Fiscal year is April - March.
Millions INR. Fiscal year is Apr - Mar.
Total Valuation
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
| 143,753 | 106,541 | 175,818 | 159,100 | - | - | |
Market Cap Growth | -16.60% | -39.40% | 10.51% | - | - | - |
Enterprise Value | 139,438 | 103,237 | 173,015 | 157,079 | - | - |
Last Close Price | 1374.10 | 1012.34 | 1660.01 | 1493.81 | - | - |
Price Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
PE Ratio | 52.37 | 40.84 | 47.31 | 51.64 | - | - |
Forward PE | 39.11 | 26.26 | 41.55 | 43.46 | - | - |
PS Ratio | 12.97 | 10.10 | 14.65 | 15.65 | - | - |
PB Ratio | 7.13 | 5.29 | 9.70 | 10.42 | - | - |
P/TBV Ratio | 7.13 | 5.29 | 9.71 | 10.42 | - | - |
P/FCF Ratio | 83.71 | 62.04 | 131.85 | 88.50 | - | - |
P/OCF Ratio | 53.86 | 39.92 | 71.90 | 59.93 | - | - |
PEG Ratio | 2.34 | 1.90 | 1.66 | 1.43 | - | - |
EV Ratios
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
EV/Sales Ratio | 12.58 | 9.79 | 14.42 | 15.45 | - | - |
EV/EBITDA Ratio | 34.25 | 27.39 | 33.57 | 35.81 | - | - |
EV/EBIT Ratio | 42.56 | 33.93 | 37.38 | 40.61 | - | - |
EV/FCF Ratio | 81.20 | 60.12 | 129.75 | 87.37 | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Debt / Equity Ratio | 0.00 | 0.00 | 0.00 | 0.01 | 0.02 | 0.06 |
Debt / EBITDA Ratio | 0.01 | 0.01 | 0.01 | 0.02 | 0.09 | 0.22 |
Debt / FCF Ratio | - | 0.01 | 0.02 | 0.05 | 0.31 | 1.19 |
Net Debt / Equity Ratio | -0.21 | -0.21 | -0.18 | -0.18 | -0.11 | -0.09 |
Net Debt / EBITDA Ratio | -1.07 | -1.14 | -0.64 | -0.62 | -0.39 | -0.36 |
Net Debt / FCF Ratio | - | -2.50 | -2.49 | -1.51 | -1.38 | -1.88 |
Asset Turnover | - | 0.49 | 0.64 | 0.63 | 0.60 | 0.57 |
Inventory Turnover | - | 1.34 | 1.93 | 1.66 | 0.94 | 0.99 |
Quick Ratio | - | 5.34 | 4.77 | 4.58 | 2.43 | 2.71 |
Current Ratio | - | 7.39 | 6.17 | 6.31 | 3.79 | 4.08 |
Return on Equity (ROE) | - | 13.54% | 22.26% | 21.88% | 20.06% | 16.64% |
Return on Assets (ROA) | - | 8.91% | 15.49% | 15.04% | 13.26% | 11.47% |
Return on Invested Capital (ROIC) | 15.35% | 14.93% | 25.43% | 24.02% | 20.75% | 17.83% |
Return on Capital Employed (ROCE) | - | 14.70% | 25.00% | 24.80% | 22.70% | 19.80% |
Yields
Fiscal Year | Current | FY 2026 | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|---|---|
Period Ending | Sep '26 Sep 30, 2026 | Mar '26 Mar 31, 2026 | Mar '25 Mar 31, 2025 | Mar '24 Mar 31, 2024 | Mar '23 Mar 31, 2023 | Mar '22 Mar 31, 2022 |
Earnings Yield | 1.92% | 2.45% | 2.11% | 1.94% | - | - |
FCF Yield | 1.19% | 1.61% | 0.76% | 1.13% | - | - |
Dividend Yield | 0.54% | 0.75% | 0.65% | 0.59% | - | - |
Payout Ratio | - | 42.90% | 24.63% | 23.19% | 22.31% | 40.31% |
Total Shareholder Return | 0.26% | 0.75% | 0.65% | 0.59% | - | - |